Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) Shares Outstanding (Weighted Average) (2020 - 2025)

Incannex Healthcare (IXHL) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $330.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1772.31% to $330.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $330.0 million through Dec 2025, up 1772.31% year-over-year, with the annual reading at $34.5 million for FY2025, 113.15% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $330.0 million in Q4 2025 for Incannex Healthcare, up from $310.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $330.0 million in Q4 2025 to a low of $15.9 million in Q3 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $76.3 million across 4 years, with a median of $17.6 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 11.03% in 2024 and later skyrocketed 1772.31% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $45.9 million in 2021, then tumbled by 65.38% to $15.9 million in 2023, then increased by 11.03% to $17.6 million in 2024, then surged by 1772.31% to $330.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for IXHL at $330.0 million in Q4 2025, $310.3 million in Q3 2025, and $34.5 million in Q2 2025.